With the Medicare Coverage for Innovative Technologies (MCIT) rule on the block, industry is trying to stop the ax from falling.
The program has been overwhelmingly welcomed by the medical device industry and seen as way of cutting through red tape to get innovative treatments to more patients faster. And in a recent letter to the Centers for Medicare & Medicaid Services (CMS), trade organization AdvaMed urged the agency not to repeal MCIT